Seattle BioMed receives $9.8 million grant for HIV vaccine
The seven-year, Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institute of Allergy and Infectious Diseases will allow Seattle BioMed to lead a consortium of universities, hospitals and research centers to develop a vaccine to elicit broadly neutralizing antibodies against HIV-1. The grant money will fund the initial phase of the project, which includes the optimization and preclinical evaluation of two vaccine candidates.
The second phase of the project will include production of the vaccines according to current good manufacturing practices and the evaluation of the immunogenicity and safety in a Phase I clinical trial.
"This grant brings together experts in vaccine-design, immunology and clinical evaluation of HIV/AIDS vaccines," Alan Aderem, the president of Seattle BioMed, said. "This multi-disciplinary collaboration will accelerate the delivery of a novel and effective vaccine to patients."
The research consortium is comprised of the Fred Hutchinson Cancer Research Center, Rockefeller University, the University of Washington and the Seattle Children's Hospital.
"The HIV-1 epidemic remains a significant threat to global health, with over three million AIDS-related deaths each year," Leonidas Stamatatos, the scientific director of Seattle BioMed, said. "While access to anti-retroviral therapies has increased, the best route of defeating the epidemic remains a universally effective HIV-1 vaccine. We look forward to continuing our collaborative research on broadly neutralizing antibodies against HIV-1."
Seattle BioMed's research serves as the foundation for new vaccines, drugs and diagnostics.